CLICKHERETO DOWNLOAD
Itisusedtotreatpatientsfromyearsofageandweighingatleastkgwhoareinfectedwithhumanimmunodeficiencyvirustype(HIV?1),avirusthatcausesacquired immunedeficiencysyndrome(AIDS)Stribildisasingle-tabletregimenforHIV.ItcontainstwodifferenttypesofHIVdrugs:oneintegraseinhibitorandtwo nucleotide/nucleosidereversetranscriptaseinhibitorsAtotalofinfusionsofPrivigenwereadministeredSTRIBILDisafour-drugfixeddosecombinationproduct containingmgofelvitegravir,mgofcobicistat,mgofemtricitabine,andmgofTDFTherecommendeddosageofSTRIBILDisonetablettakenorallyoncedaily withfoodinadultsandpediatricpatientsyearsofageandolderwithabodyweightatleastkgSTRIBILDisafour-drugcombinationofelvitegravir,anHIV integrasestrandtransferinhibitor(HIVINSTI),cobicistat,aCYP3Ainhibitor,andemtricitabineandtenofovirDF,bothHIVStribildisindicatedforthetreatment ofhumanimmunodeficiencyvirus(HIV-1)infectioninadultsagedyearsandoverwhoareantiretroviraltreatment-naïveorareinfectedwithHIVwithoutknown mutationsassociatedwithresistancetoanyofthethreeantiretroviralagentsinStribild(seesections,and)Theonlyuseofcobicistat(COBI)isasa pharmacokinetic(PK)enhancer(boostingagent)forcertainproteaseinhibitors(PIs)andintegrasestrandtransferinhibitors.•STRIBILDisacompleteregimenfor thetreatmentofHIVinfection;therefore,STRIBILDshouldnotbeadministeredwithotherantiretroviralmedicationsfortreatmentofHIV(Stribildgroupn=; ritonavir-boostedatazanavir(ATV/r)plusemtricitabine(FTC)/tenofovirdisoproxilgroupn=)TheapplicationforStribildwaspresentedtotheAntiviralDrugs AdvisoryCommitteeThemediandoseofPrivigenadministeredwasmg/kg(3-weekschedule)ormg/kg(4-weekschedule)andrangedfromtomg/kgTablet: DiscontinuedbythemanufacturerMeanpercentagereasesinBMDfrombaselinetoWeekSTRIBILDisafixeddosecombinationofelvitegravir,cobicistat, emtricitabineandtenofovirDFItshouldnotbeco-administeredwithanyotherantiretroviralagentsbecause:STRIBILDisafour-drugfixeddosecombination productcontainingmgofelvitegravir,mgofcobicistat,mgofemtricitabine,andmgofTDF.TherecommendedWHATISSTRIBILD?Elvitegravirisavailable onlyinfixed-dosecombination(FDC)tabletsSUSTIVA(efavirenz)shouldnotbecoadministeredwithATRIPLAunlessalsoincludesapatientpackageinsert thatprovidesinformationaboutStribildStribildisacompleteHIVregimenusedaspartofantiretroviraltherapy(ART)Stribildcontainsfourantiretroviraldrugs (ARVs)combinedinonetabletCOMPLERA,EMTRIVA,STRIBILD,TRUVADA,orVIREAD;orwithdrugscontaininglamivudineYoucanreportside effectstoFDAatFDA()oronlineTolearnmoreaboutpossiblesideeffectsofStribild,readthedruglabelorpackageinsertortalktoyourhealthcareprovider orpharmacist[Stribild]Elvitegravirmg/cobicistatmg/emtricitabinemg/tenofovirStribildisamedicinethatcontainstheactivesubstanceselvitegravir,cobicistat, emtricitabineandtenofovirdisoproxilCOBIisnotinterchangeablewithritonavir(RTV)andhasnoantiviralactivity[Genvoya]Elvitegravirmg/cobicistat mg/emtricitabinemg/tenofoviralafenamidemg.FDCTablets.ChildandAdolescent(Weighing≥kg)andAdultDoseElvitegravir(EVG)Formulations.Italso containsapharmacokineticenhancer,adrugthathasnoactivityagainstHIV,butitbooststhebloodlevelsandeffectivenessofotherdrugsThesearenotallthe possiblesideeffectsofStribild